Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the therapeutic efficacy of Decitabine in patients with
chronic myelomonocytic leukemia (CMML) diagnosis according to WHO criteria either untreated
or previously treated with Hydrea or Etoposide (given orally), non intensive chemotherapy or
intensive chemotherapy given more than 3 months before inclusion.